The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).

BACKGROUND We previously correlated non-Hodgkin's lymphoma (NHL) histology with (18)fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) intensity: a standardized uptake value (SUV)>10 predicted aggressive lymphoma with >80% certainty and an SUV >13, with >90% certainty. PATIENTS AND METHODS To evaluate SUV in transformed lymphoma, we identified all FDG-PET scans for NHL at Memorial Sloan-Kettering Cancer 1999-2007 with (i) biopsy-proven transformation, (ii) no therapy 60 days before PET scan and (iii) FDG-PET scans no more than 60 days before or 90 days after transformation. RESULTS In 5 of 40 patients, the biopsy site was excised before PET; in two, only marrow was biopsied. In the remaining 33 patients, the SUV of the biopsy site ranged from 3 to 38, mean 14, median 12. Eighteen of 33 biopsies (55%) had an SUV>10 and 16 (48%)>13. The highest SUV in a transformed lymphoma PET scan (SUV(study-max)) ranged from 3.2 to 40, mean 15, median 12. Twenty-five of 40 patients (63%) presented with an SUV(study-max)>10 and 20 (50%)>13. CONCLUSIONS Like de novo aggressive lymphomas, the majority of transformations have a high SUV(study-max) for a given pretreatment staging study, although many do not have very high values. Transformation should be suspected in indolent lymphoma with high SUVs on FDG-PET. Biopsies should be directed to the site of greatest FDG avidity.

[1]  T. Mattfeldt,et al.  Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.

[2]  E. Giné,et al.  The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Vicini,et al.  Accelerated partial breast irradiation as a part of breast conservation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Mithat Gonen,et al.  Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Schirrmeister,et al.  2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.

[8]  Sung-Cheng Huang,et al.  Anatomy of SUV , 2000 .

[9]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[11]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[12]  J. D. van der Walt,et al.  Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.

[13]  E. Merkle,et al.  Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.

[14]  M E Phelps,et al.  Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  S. Horning,et al.  Long-term survival after histologic transformation of low-grade follicular lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. J. Conover,et al.  Practical Nonparametric Statistics , 1972 .

[17]  S C Huang,et al.  Anatomy of SUV. Standardized uptake value. , 2000, Nuclear medicine and biology.

[18]  J. Diebold,et al.  Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.